Driessen, M. T., Whalen, J., Seewoodharry Buguth, B., Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., . . . Risebrough, N. A. (2018). Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective.
Citación estilo ChicagoDriessen, M. T., et al. Cost-effectiveness Analysis of Umeclidinium Bromide/vilanterol 62.5/25 Mcg Versus Tiotropium/olodaterol 5/5 Mcg in Symptomatic Patients With Chronic Obstructive Pulmonary Disease: A Spanish National Healthcare System Perspective. 2018.
Cita MLADriessen, M. T., et al. Cost-effectiveness Analysis of Umeclidinium Bromide/vilanterol 62.5/25 Mcg Versus Tiotropium/olodaterol 5/5 Mcg in Symptomatic Patients With Chronic Obstructive Pulmonary Disease: A Spanish National Healthcare System Perspective. 2018.